The rapid growth and competition in the generics market has placed significant pressure on generic drug developers to attain first to market designation for their products. We understand this speed to market requirement means that you need a CRO who can work within urgent timelines and strict budgets. We will manage your study with rigor, as we have successfully managed multiple bioequivalence clinical endpoint studies across a number of therapeutic domains.
TCTM has met or exceeded 100% of the enrollment milestones and CSR delivery dates on all bioequivalence studies that we have managed since our inception. If you are looking for a CRO that can consistently deliver these types of results, contact us and experience the Total Touch.